Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Vertex Pharmaceuticals slipped 1.41% to close at $475.49, managing to outperform a much gloomier market where the S&P 500 nose-dived 3.46%. Despite the drop, Vertex flexed its resilience, outpacing ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...